IN THE UNITED STATES PATENT AND TR

Appl. No.

: National Phase Entry of PCT/EP03/013655

Applicant

: MEISE et al

Filed

: Herewith

TC/A.U.

Examiner

Docket No.

: 2923-703

Customer No.: 6449

Confirmation No. :

## **INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with applicants duty of disclosure under 37 C.F.R. 1.56, enclosed is a copy of the International Search Report in the corresponding international application. The relevance of the references is noted in the International Search Report. We understand that the references have been forwarded by the International Bureau, and are available to the Examiner, but if the Examiner needs copies of any of the references, the Examiner is requested to advise counsel accordingly.

In the event that any fees are due with this paper, please charge our Deposit Account No. 02-2135.

Respectfully submitted,

Robert B. Murray

Attorney for Applicant

Registration No. 22,980

ROTHWELL, FIGG, ERNST & MANBECK

1425 K. Street, Suite 800 Washington, D.C. 20005

Telephone: (202) 783-6040

RBM/cb

## JC17 Recd PCT/PTO 02 JUN 2005

<u> </u>				Complete if Known		
				Application Number	New Apple of Billing 03	
INFORMATION DISCLOSURE				Filing Date	Herewith	
STATEMENT BY APPLICANT			N I	First Named Inventor	MEISE et al	
				Group Art Unit		
				Examiner Name		
				Confirmation No.		
Sheet	1	of	2	Attorney Docket Number	2923-703	

_			FOF	REIGN PAT	TENT DOCUMENTS		
Examiner Initials*	Cite No.1	Office <sup>3</sup>	Foreign Patent Docur	Kind⁵	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T6
		Code		(if known)			+
	1.	W0	97/06262	Α	Incyte Pharma Inc.	2/20/97	$oldsymbol{\perp}$
	2.	wo	99/14340	A	Incyte Pharma Inc.	3/25/99	igg
							+
							_
							+
					-		$\dagger$
		1					$\downarrow$
-							+
Examiner Signature		<u> </u>	l		Date Considered		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

JC17 Rec'd PCT/PTO 02 JUN 2005

				Complete if Known		
				Application Number	New Appleatain 303	
INFORMATION DISCLOSURE				Filing Date	Herewith	
STATEMENT BY APPLICANT			NI	First Named Inventor	MEISE et al	
				Group Art Unit		
				Examiner Name		
			_	Confirmation No.		
Sheet	2	of	2	Attorney Docket Number	2923-703	

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(spublisher, city and/or country where published					
	3.	Kadambi et al., "Impaired ventricular relaxation resulting from cardiac-specific overexpression of a human prenylated protein tyrosine phosphatase", CIRCULATION, vol. 102, no. 18 Supplement, 31 October 2000, pg. II. 268.					
	4.	Hoit et al., "Restrictive cardiomyopathy in transgenic mice with cardiac-specific overexpression of a tyrosine phosphatase, PRL-3", CIRCULATION, vol. 104, no. 17 Supplement, 23 October 2001, pg. II.164					
Examiner Signature		Date Considered					

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.